Odylia Therapeutics is a 501(c)(3) organization, classified under Medical Research (NTEE H41). Contributions are tax-deductible.
830 Glenwood Ave Se Ste 510 Pmb 32, Atlanta, GA 30316-2176
Among the 12 scored medical research organizations in Atlanta, Odylia Therapeutics holds 7 months of operating reserves (peer median 7.8 months), runs a typical yearly deficit of 11.4% (peers: deficit of 3.0%), and has grown spending 17.5% a year (peers: grown spending 13.1% a year).
In fiscal year 2025 it reported $1,523,364 in revenue and $1,406,969 in expenses, with contributions making up 59.0% of revenue.
Odylia utilizes a unique, non-profit model to develop and advance therapeutics for people with rare diseases, changing the way treatments are brought from the lab to the clinic.
Main program · fiscal year 2025
Odylia's two primary initiatives are the odylia pipeline and brydge solutions. The pipeline includes the rpgrip1, ush1c, and nphp1 gene therapy programs. Significant accomplishments included a successful fda pre-ind meeting and preclinical development activities for the rpgrip1 program, clinical candidate selection and delivery optimization for the ush1c program, and initial vector design and test… Read more
Odylia's two primary initiatives are the odylia pipeline and brydge solutions. The pipeline includes the rpgrip1, ush1c, and nphp1 gene therapy programs. Significant accomplishments included a successful fda pre-ind meeting and preclinical development activities for the rpgrip1 program, clinical candidate selection and delivery optimization for the ush1c program, and initial vector design and testing for the nphp1 program. Brydge solutions accelerates the development of treatments for rare diseases through strategic partnerships with patient advocacy organizations, disease foundations, and rare disease families. In 2025, the program established five new partnerships with save sight now, med13l foundation, upstream genes, dlg4 shine syndrome foundation, and pbd project.
$1,197,948 spent
Where each dollar went · fiscal year 2025
Of every dollar it spent, 85¢ went to programs, 8¢ to management and 7¢ to fundraising.
Programs $1,197,948
Management $106,241
Fundraising $102,780
In the organization's own words to the IRS, shown for context. None of this affects the America's Best Score, and a Form 990 describes programs without measuring their results.
Spending on programs Not scored; America's Best needs 65%+
85%
Meets
Compared with Atlanta peers
Measure
This organization
Peer median
Operating reserves
7.0 mo
7.8 mo
Typical margin
−11.4%
−3.0%
Spending growth
+17.5% / yr
+13.1% / yr
Debt load
52.9%
17.8%
Peers: the 12 Atlanta medical research organizations with a score, ranked or below the bar.
Tax filings by year
Financial data extracted from the Form 990 the organization filed with the IRS for each fiscal year. Revenue lines can exceed 100% when other items, such as fundraising event costs, are netted against total revenue.
Revenue$1,523,364Fiscal year 2025
Expenses$1,406,969Fiscal year 2025
Total assets$1,741,781Fiscal year 2025
Total liabilities$921,012Fiscal year 2025
Fiscal year ending December2025
Revenue$1,523,364
Expenses$1,406,969
Net income$116,395
Net assets$820,769
Notable sources of revenue
Percent of total revenue
Contributions
$898,455
59.0%
Program services
$609,083
40.0%
Investment income
$15,826
1.0%
Other (net)
$0
0.0%
Assets / debt
Total assets
$1,741,781
Total liabilities
$921,012
Net assets
$820,769
Compensation
Not in our extract for this year.
Fiscal year ending December2024
Revenue$482,047
Expenses$699,405
Net income−$217,358
Net assets$687,556
Notable sources of revenue
Percent of total revenue
Contributions
$291,256
60.4%
Program services
$144,417
30.0%
Investment income
$46,374
9.6%
Other (net)
$0
0.0%
Assets / debt
Total assets
$1,594,795
Total liabilities
$907,239
Net assets
$687,556
Compensation
Not in our extract for this year.
Fiscal year ending December2023
Revenue$570,773
Expenses$867,236
Net income−$296,463
Net assets$9,647,308
Notable sources of revenue
Percent of total revenue
Contributions
$289,283
50.7%
Program services
$241,089
42.2%
Investment income
$40,401
7.1%
Other (net)
$0
0.0%
Assets / debt
Total assets
$9,688,644
Total liabilities
$41,336
Net assets
$9,647,308
Compensation
Officers and key employees
$230,695
Share of expenses
26.6%
Fiscal year ending December2022
Revenue$1,098,401
Expenses$866,473
Net income$231,928
Net assets$9,925,894
Notable sources of revenue
Percent of total revenue
Contributions
$976,484
88.9%
Program services
$107,361
9.8%
Investment income
$14,556
1.3%
Other (net)
$0
0.0%
Assets / debt
Total assets
$10,021,651
Total liabilities
$95,757
Net assets
$9,925,894
Compensation
Officers and key employees
$210,664
Share of expenses
24.3%
About this data
Figures come from IRS Form 990 filings, through the IRS Exempt Organizations Business Master File (2026-11-09) and e-filed returns. Form 990 data typically lags 12–24 months behind an organization's fiscal year. Found an error?